Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)

NCT04474847 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT04474847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04474847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)
Lead sponsor
University of Pennsylvania
Phase
Phase 3
Overall status
Recruiting
Start date
March 29, 2021
Completion date
December 31, 2029
Enrollment
78 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

giant cell arteritis